High-Grade Pleomorphic Sarcomas Treated with Immune Checkpoint Blockade: The MD Anderson Cancer Center Experience.
Lewis Fady NasrMarianne ZoghbiRossana LazcanoMichael NakazawaAndrew J BishopAhsan S FarooqiDevarati MitraBeverly Ashleigh GuadagnoloRobert BenjaminShreyaskumar PatelVinod RaviDejka M AraujoAndrew LivingstonMaria Alejandra ZarzourAnthony P ConleyRavin RatanNeeta SomaiahAlexander J LazarChristina Lynn RolandEmily Z KeungElise F Nassif HaddadPublished in: Cancers (2024)
Real-world retrospective data are consistent with the published literature, with a promising 6-month PFS of 32%. Partial or stable responders to ICB treatment have significantly improved PFS compared to progressors.